Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Duchenne Muscular Dystrophy · Muscular Dystrophy, Duchenne · SRPT

Sarepta Therapeutics

Sarepta Therapeutics clinical programs — 18 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
215 First Street, Cambridge, MA 02142, US HQ
1,150 Employees
Public company Type
SRPT · NYSE Ticker
Company details
Status
Public
HQ
215 First Street, Cambridge, MA 02142, US
Employees
1,150
Programs
46
Drugs
23
Patents
102
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Sarepta Therapeutics projects

18 ClinicalTrials.gov programs sponsored by Sarepta Therapeutics.

Sarepta Therapeutics has 18 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

18 programs

Clinical programs

  1. ARODM1-1001

    Sarepta Therapeutics

    Type 1 Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  2. AVI-4065 Injection

    Sarepta Therapeutics

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  3. AVI-4658 (Eteplirsen)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule completed

    1 trial

  4. AVI-4658 (Eteplirsen)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  5. AVI-4658 (PMO)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  6. AVI-4658 for Injection

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  7. AVI-5126

    Sarepta Therapeutics

    Cardiovascular Disease

    phase 2 small molecule terminated

    1 trial

  8. Amondys 45

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  9. Eteplirsen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    2 trials

  10. Placebo

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  11. RESTEN-MP

    Sarepta Therapeutics

    Coronary Artery Disease

    phase 2 small molecule completed

    2 trials

  12. SODIUM CHLORIDE, ARO-DUX4

    Sarepta Therapeutics

    Facioscapulohumeral muscular dystrophy (FSHD)

    phase 2 small molecule active

    1 trial

  13. SRP-5051

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 2 small molecule terminated

    2 trials

  14. SRP-9003

    Sarepta Therapeutics

    Limb-Girdle Muscular Dystrophy, Type 2E

    phase 2 gene therapy terminated

    1 trial

  15. SRP-9004

    Sarepta Therapeutics

    Limb-Girdle Muscular Dystrophy, Type 2D

    phase 2 gene therapy completed

    1 trial

  16. VESLETEPLIRSEN(SRP-5051)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  17. Vesleteplirsen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  18. delandistrogene moxeparvovec

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 2 gene therapy active

    2 trials

Frequently asked questions

How many clinical projects does Sarepta Therapeutics have?

18 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.